Veeva Systems is a cloud software company that makes the mission-critical digital tools drug and biotech companies use to manage everything from clinical trials to sales. It generated $3.20 billion in revenue for the fiscal year ended January 2026, growing 16% over the previous year. Veeva is currently in the middle of a major shift: moving its massive customer base from Salesforce technology onto its own proprietary platform, Vault CRM.
The investment thesis on Veeva Systems is that this platform migration will significantly expand its profit margins by removing third-party licensing fees while deepening its grip on the life sciences industry. Veeva's software is so deeply embedded in the complex regulatory workflows of pharma giants that switching to a competitor is a multi-year risk most companies avoid.
We think Veeva is one of the highest-quality software businesses in the market, and its recent stock performance has not yet reflected the long-term margin benefits of its platform shift. If the company successfully moves its 1,500+ customers onto its own technology while maintaining its dominant market share, the cash flow growth over the next five years will be substantial.
Veeva Systems stock has dropped significantly over the past few years as investors grew impatient with the company’s progress. The price is down roughly half from where it was five years ago. This happened because the company is currently rebuilding its own software platform from scratch to stop paying fees to others, which has made the business more complicated.
What does it do?
Veeva Systems is a maturing business that earns money by selling specialized cloud software and data services to companies in the life sciences industry. Drug companies use Veeva to manage the thousands of documents required for clinical trials, ensure they are following government regulations, and track every interaction their sales reps have with doctors. Veeva makes money primarily through multi-year subscriptions, which provide a highly predictable stream of recurring revenue. Customers pay an annual fee per user or per product module, and because this software is essential for complying with strict FDA rules, drug companies rarely cancel.
Where does revenue come from?
Veeva gets over 80% of its revenue from subscription fees, which grow as customers add more users or buy new software modules. Subscription revenue reached $730.2 million in the most recent quarter, representing 83% of the total. The company breaks this down into two main buckets: Commercial Cloud, which helps sales teams market drugs, and the faster-growing Development Cloud (Vault), which helps scientists manage the drug-making process. Geographic data shows that while North America is the largest market, Veeva has a global reach across Europe and Asia.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Veeva Systems serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to small, emerging biotechs. This customer base includes almost every major name in the industry, including Pfizer, GSK, and Eli Lilly. Veeva has successfully sold more products to its existing users over time; for example, it added 27 new Vault CRM customers in the first quarter of FY2027, bringing the total number of live customers on that new platform to over 150. Total revenue reached $3.20 billion in FY2026, supported by high retention rates as companies find it difficult to move their massive data sets to other providers.
What gives it staying power?
Veeva has high switching costs because its software is the "system of record" for drug companies, meaning it holds the critical data needed for regulatory approval. If a pharma company were to leave Veeva, it would have to retrain thousands of employees and risk data errors that could delay a multi-billion dollar drug launch.
Where is it headed?
Veeva is making a massive strategic bet on "Agentic AI," which uses AI agents to automate labor-heavy tasks in drug development and sales. CEO Peter Gassner wants to transform Veeva from a simple software provider into an AI-driven partner that can write clinical reports or answer medical questions automatically. This is designed to increase productivity for pharma customers and allow Veeva to charge more for its advanced software.
Veeva is maintaining steady double-digit growth, with revenue reaching $3.20 billion in the most recent fiscal year. The business is in an enviable position where revenue is growing at 16% while net income is growing at nearly the same pace, showing that the company does not have to sacrifice profit to find new sales.
Cash generation is exceptional, with free cash flow of $1.39 billion in FY2026 easily exceeding net income of $0.91 billion. This high "cash conversion" happens because Veeva collects subscription payments upfront while its software-based model requires very little physical equipment or expensive building projects.
Veeva has one of the cleanest balance sheets in the software industry, carrying $7.31 billion in cash and investments and almost zero debt. This massive cash pile gives management total flexibility to fund new AI research or acquire smaller competitors without ever needing to borrow from a bank.
Veeva is a financially elite software business with high margins, rising cash flows, and a fortress-like balance sheet that allows it to invest through any economic cycle.
The shift to the proprietary Vault CRM platform is moving faster than expected, with over 150 customers already live on the new technology. This is the most important financial driver because it allows Veeva to eventually stop paying technology fees to Salesforce, which will likely push operating margins toward the 34% range in the coming years.
Subscription revenue growth, while still strong at 15%, is the key metric that must not slow down as the market for sales software matures. If large pharma companies tighten their budgets and stop buying new software modules, Veeva’s growth could stall before the full margin benefits of the new platform kick in.
The life sciences cloud software market is roughly $15 billion today and is growing about 12% annually as drug companies move their old computer systems to the cloud. This is an exceptional industry because drug companies prioritize reliability and regulatory compliance over price, which gives software providers high pricing power. Veeva is the clear leader in this niche market, and its growth runway remains long as pharma companies increasingly digitize their R&D and clinical trial operations.
The competitive dynamic in life sciences software is defined by high barriers to entry because any new software must meet strict global safety and data standards. Most customers prefer to buy from a specialist like Veeva rather than a generic software giant because the cost of a data error is a failed drug trial.
IQVIA and Dassault Systèmes (via Medidata) are the most formidable threats because they have deep historical relationships with pharma companies. Salesforce is a unique threat; as Veeva moves customers to its own platform, Salesforce may try to win those customers back with its own life sciences version. The biggest risk is if a competitor bundles data and software together at a lower price to undercut Veeva's premium position.
Veeva is currently holding its ground and gaining share in the R&D space, which is why revenue grew 16% last year despite a maturing sales software market.
Veeva's primary protection is the massive switching costs drug companies face when they store their most sensitive clinical trial data on Veeva's servers. Moving that data to a competitor is not just a technical headache; it is a regulatory risk that could lead to drug approval delays worth billions in lost sales. This creates a "lock-in" effect that keeps customers paying for decades.
The numbers reflect this strength: Veeva maintains a 75% gross margin and an ROIC of nearly 10%, even while holding a massive $7.3 billion cash pile that usually drags that percentage down. These metrics prove that Veeva has a genuine structural edge that allows it to generate high profits without being forced to compete on price.
The moat is strengthening as Veeva moves customers onto its own Vault CRM platform, giving it total control over the technology and improving its profit margins.
Exceeded guidance on all metrics in Q1 FY2027 while raising full-year outlook.
Generated $1.39B in FCF in FY2026 with $7.3B cash and zero debt.
Founder Peter Gassner remains CEO and holds a substantial personal stake in the company.
Capital Allocation Track Record
Peter Gassner is widely considered one of the best operators in enterprise software, having founded Veeva after leading the product team at Salesforce. His decision to move Veeva away from Salesforce's infrastructure was a bold and potentially risky strategic bet that is now paying off, as evidenced by the successful migration of over 150 early customers to Vault CRM. This management team is exceptionally disciplined, refusing to engage in value-destructive acquisitions and maintaining a debt-free balance sheet that provides a massive margin of safety.
The primary governance risk is Veeva's heavy reliance on Gassner's vision, though the company has built a deep bench of experienced leaders like CFO Brian Van Wagener. While there are no immediate succession concerns, the company's "Agentic AI" pivot is highly dependent on Gassner's ability to stay ahead of technology shifts. Veeva's status as a Public Benefit Corporation is also notable, as it legally requires the board to balance shareholder returns with the interests of the life sciences industry, which management believes actually increases long-term loyalty from pharma customers.
We expect revenue to grow from $3.2B in FY2026 to $5.5B in FY2031 (~12% CAGR), with EPS growing from $7.94 to $14.64 (~13% CAGR). Growth is sustained by the migration of the core customer base to the proprietary Vault CRM platform and continued expansion into clinical data management software. Profitability improves as the company eliminates third-party licensing fees by moving customers from Salesforce onto its own cloud infrastructure. EPS grows faster than revenue because profit margins expand as the company shifts to its own technology platform. Operating margin expected to reach ~34% by FY2031.
Platform migration eliminates licensing fees and lifts margins. As customers move to Vault CRM, Veeva stops paying Salesforce royalties, allowing profit to grow significantly faster than revenue.
AI agents automate clinical trial reports and sales tasks. High-value AI features create a new premium tier of products that can increase the average amount each customer pays.
Development Cloud becomes the standard for clinical data. If Veeva Vault becomes the universal system for clinical trials, it creates a "winner-take-most" dynamic in the drug research market.
Migration to Vault CRM hits technical or adoption friction. If major customers refuse to move or experience data losses during the shift, it would damage Veeva's reputation for reliability.
Salesforce launches a direct, aggressive life sciences competitor. Salesforce has the scale and relationships to fight for Veeva's core customers as their partnership agreement winds down.
Pharma industry consolidation reduces the number of paying customers. Mergers between giant drug companies often lead to "seat consolidation" and lower total spending on software licenses.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach (price-to-earnings applied to next year's earnings) as our primary valuation framework. This fits Veeva because it is a mature, GAAP-profitable software business with highly predictable subscription revenue and a clear path to margin expansion. Using a multiple of future earnings captures the market's willingness to pay for Veeva's high-quality "moat" (competitive advantage) as it transitions into an independent technology stack.
Next year's (FY2027) EPS of $9.06 multiplied by a 30x multiple gives a per-share fair value of $272. A 30x multiple sits at the higher end of the vertical software peer range (Salesforce at 25x, IQVIA at 20x, Adobe at 28x), which is justified by Veeva’s superior 75% gross margins and its essential role in the regulated life sciences industry. We use the FY2027 EPS of $9.06 from the projection engine, which accounts for the revenue growth and margin benefits of the Salesforce transition.
Cross-checked with a 5-year Discounted Cash Flow (DCF) model, we get a fair value of $311—within 13% of our P/E-based answer of $272, confirming the result. This DCF (the present value of all future cash the business will produce) uses a 10% discount rate and a 33x terminal multiple. The higher DCF value suggests that our 30x Forward P/E is conservative, as it doesn't fully capture the compounding effect of the margin expansion in the later years (FY2028-FY2031) when EPS growth is expected to remain in the mid-teens.
We're assuming operating margins structurally expand by approximately 400-600 basis points over the next 24 months. This is driven by the completion of the Vault CRM migration, which eliminates the licensing fees Veeva previously paid to Salesforce for every user. Management has already demonstrated this leverage in recent prints, with non-GAAP margins reaching 46%.
We're assuming Veeva maintains its "Wide Moat" status and 95%+ retention rates within the top 20 global pharmaceutical companies. Life sciences software is deeply regulated; switching costs are enormous because changing platforms requires complex data re-validation and regulatory filings. Recent enterprise deals, like the long-term partnership with BioMarin, suggest this "stickiness" remains intact despite new market entrants.
We're assuming the company's new AI "agents" begin contributing to revenue by late FY2027. The launch of Veeva Falcon MLR and AI agents for Vault CRM targets "agentic labor"—using software to handle manual content reviews. This shifts the value proposition from just providing a tool to providing the actual labor, which justifies the premium multiple we apply to future earnings.
The biggest risk is intensifying competition from Salesforce, which has launched a direct rival to Veeva's core customer relationship management software. This could force Veeva to compete on price for the first time, compressing its forward multiple from 30x to 22x and knocking roughly $72 off the per-share fair value. Watch for any mention of "pricing pressure" or "competitive discounting" in the next three quarterly reports.
Bear case ($185): Salesforce Life Sciences Cloud wins more than 10 top-20 pharma CRM accounts by end of FY2027; or Subscription revenue growth decelerates below 12% as R&D spending in biotech remains cautious.
Bull case ($335): Operating margins expand by more than 500 basis points in FY2027 as Vault CRM migration completes ahead of schedule; or "Agentic AI" tools (software that performs tasks autonomously) drive a 20% increase in average revenue per customer.
Clearthesis wrote this report from 39 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is bullish because Veeva is successfully migrating its massive customer base onto its own platform to capture higher margins. By ditching third-party Salesforce licensing fees for its proprietary Vault CRM, Veeva keeps more profit from every sale while making its software essential for running clinical trials and sales operations.
Skeptics think that moving every client to a new proprietary platform carries significant execution risk for the company. If the transition to Vault CRM encounters technical friction or causes customers to pause their service, Veeva could see its steady 16 percent growth rate stall abruptly during the migration.